Boswellia
Boswellia serrata (Indian Frankincense)
Potent anti-inflammatory resin extract with strong evidence for joint pain, arthritis, and inflammatory conditions.
Boswellia serrata, also known as Indian frankincense, contains boswellic acids that inhibit 5-lipoxygenase (5-LOX), a key inflammatory enzyme. Unlike NSAIDs, it doesn't damage the gut lining. Clinical evidence strongly supports its use for osteoarthritis, rheumatoid arthritis, and inflammatory bowel conditions. One of the best-researched herbal anti-inflammatories.
Mechanisms of Action
5-LOX Inhibition
Blocks a key inflammatory enzyme
Cartilage Protection
Protects joint cartilage from degradation
Recommended Dose
300-500mg standardized extract (30-40% AKBA), 2-3x daily
Optimal Timing
- With meals containing fat
Take with food
Best Form
Standardized extract (30-40% AKBA or 65% boswellic acids)
Alternatives: 5-Loxin (30% AKBA), ApresFlex (20% AKBA, enhanced bioavailability)
ApresFlex and 5-Loxin are patented forms with good research. Higher AKBA content generally means higher potency.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Fat improves absorption of boswellic acids. Split into 2-3 doses throughout the day.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Joint Pain Relief
Significant reduction in OA and RA pain
Improved Mobility
Better joint function and flexibility
Reduced Swelling
Less joint inflammation
Avoid — may stimulate uterine contractions
Who Should NOT Take This
- Known allergy or hypersensitivity to Boswellia or related compounds
- Pregnancy and breastfeeding
Drug Interactions
Theoretical antiplatelet effects — may affect platelet aggregation or vitamin K-dependent clotting factors, altering anticoagulant efficacy
May have additive anti-inflammatory effects
Possible Side Effects
Tip: Take with food
Tip: Take with meals
Warnings
- Avoid during pregnancy
- Takes 4-8 weeks for full benefit — be patient
Curcumin
complementaryDifferent anti-inflammatory pathways (5-LOX vs COX)
Comprehensive inflammation control
Glucosamine
complementaryBoswellia reduces inflammation; glucosamine supports cartilage
Complete joint support
Cat's Claw
complementaryDifferent anti-inflammatory mechanisms
Enhanced joint and inflammation support
White Willow Bark
complementaryDifferent anti-inflammatory pathways
Enhanced pain and inflammation relief
Top studies from 40+ peer-reviewed papers
Zhang Y et al. • Nutrients (2025)
“However, further large-scale, well-designed randomized controlled trials (RCTs) are needed to confirm these findings, particularly those that include more standardized dosages and formulations, as well as to evaluate their long-term efficacy.”
Key Findings:
- Bayesian rankings indicated Boswellia had the highest probability of being most effective for pain and stiffness, with krill oil and curcumin showing potential for function improvement.
- Conclusions: Nutritional supplements, particularly Boswellia, appear to be effective and well-tolerated for improving KOA symptoms and function.
- These results suggest that certain supplements may be useful as part of non-pharmacological KOA management.
- However, further large-scale, well-designed randomized controlled trials (RCTs) are needed to confirm these findings, particularly those that include more standardized dosages and formulations, as well as to evaluate their long-term efficacy.
Del Grossi Moura M et al. • Phytotherapy research : PTR (2017)
“Copyright © 2017 John Wiley & Sons, Ltd.Copyright © 2017 John Wiley & Sons, Ltd.”
Key Findings:
- Z. officinale showed improvement of pain over placebo.
- The evidence was insufficient to support the effective and safe use of these herbal medicines, because the quality of evidence of studies was low.
- This study guides managers of the Brazilian public health system and prescribers in decision-making regarding the use of these herbal medicines for OA.
- Copyright © 2017 John Wiley & Sons, Ltd.Copyright © 2017 John Wiley & Sons, Ltd.
Cameron M et al. • The Cochrane database of systematic reviews (2014)
“Evidence for the proprietary ASU product Piasclidine® in the treatment of osteoarthritis symptoms seems moderate to high for short term use, but studies over a longer term and against an apparently active control are less convincing.”
Key Findings:
- Seventeen studies of confirmatory design (sample and effect sizes pre-specified) were mostly at moderate risk of bias.
- Physical function was 33 points on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 0 to 100 point subscale (0 is no loss of function) with placebo, enriched Boswellia serrata improved function by 8 points (95% CI 2 to 14); NNTB 4.
- Moderate-quality evidence (one study, 96 participants) indicated that adverse events were probably reduced with enriched Boswellia serrata (18/48 events versus 30/48 events with placebo; relative risk (RR) 0.60, 95% CI 0.39 to 0.92).
- Mean pain with placebo was 40.5 points on a VAS 0 to 100 scale (0 is no pain), ASU 300 mg reduced pain by a mean of 8.5 points (95% CI 1 to 16 points); NNTB 8.
Dalmonte T et al. • Phytotherapy research : PTR (2024)
“Phytotherapy Research published by John Wiley & Sons Ltd.”
Key Findings:
- More than 40% of patients use complementary and alternative medicine including supplements containing phytoextracts with anti-inflammatory properties as those from the Boswellia genus.
- This was also confirmed in the meta-regression applied to the WOMAC scores.
- This is an important finding as people exposed to NSAID-related adverse effects could benefit from the use of Boswellia extracts.
- However, further high-quality studies are needed to establish the clinical efficacy of extracts from the genus Boswellia.© 2024 The Author(s).
Dubey V et al. • Explore (New York, N.Y.) (2024)
“BS supplementation is effective OA symptomatic management.”
Key Findings:
- BS supplementation significantly reduced VAS (MD: -10.71; p<0.00001), LFI (MD: -2.99; p<0.00001), WOMAC-pain (MD: -10.69; p<0.0001), WOMAC-stiffness (MD: -5.49; p<0.00001), and WOMAC-function (MD: -10.69; p<0.00001) scores compared to control therapy.
- BS supplementation is effective OA symptomatic management.
- Sub-group analysis revealed that AflapinⓇ supplementation may be better in improving the symptoms of OA which needs to be confirmed by more comparative clinical studies.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.